Abstract-Calcitonin gene-related peptide (CGRP) is a powerful vasodilator that interacts with the autonomic nervous system. A subunit of the CGRP receptor complex, receptor activity-modifying protein 1 (RAMP1), is required for trafficking of the receptor to the cell surface and high-affinity binding to CGRP. We hypothesized that upregulation of RAMP1 would favorably enhance autonomic regulation and attenuate hypertension. Blood pressure, heart rate, and locomotor activity were measured by radiotelemetry in transgenic mice with ubiquitous expression of human RAMP1 (hRAMP1) and littermate controls. Compared with control mice, hRAMP1 mice exhibited similar mean arterial pressure, a lower mean heart rate, increased heart rate variability, reduced blood pressure variability, and increased baroreflex sensitivity (2.83Ϯ0.20 versus 1.49Ϯ0.10 ms/mm Hg in controls; PϽ0.05). In control mice, infusion of angiotensin II (Ang-II) increased mean arterial pressure from 118Ϯ2 mm Hg to 153Ϯ4 and 174Ϯ6 mm Hg after 7 and 14 days of infusion, respectively (PϽ0.05). In contrast, Ang-II hypertension was markedly attenuated in hRAMP1 mice with corresponding values of mean arterial pressure of 111Ϯ2, 119Ϯ2, and 132Ϯ3 mm Hg. Ang-II induced decreases in baroreflex sensitivity and heart rate variability, and increases in blood pressure variability observed in control mice were also abrogated or reversed in hRAMP1 mice (PϽ0.05). Moreover, during the Ang-II infusion, the pressor response to the CGRP receptor antagonist CGRP 8-37 was significantly greater (PϽ0.05) in hRAMP1 mice (ϩ30Ϯ2 mm Hg) than in control mice (ϩ19Ϯ2 mm Hg), confirming a significantly greater antihypertensive action of endogenous CGRP in hRAMP1 mice. We conclude that RAMP1 overexpression attenuates Ang-II-induced hypertension and induces a protective change in cardiovascular autonomic regulation. (Hypertension. 2010;55:627-635.)
C alcitonin gene-related peptide (CGRP) is expressed predominantly in the nervous system and contributes to a variety of physiological and pathological processes, including neurogenic inflammation, inhibition of cell proliferation and oxidative stress, and cardiovascular regulation. 1, 2 CGRP is one of the most powerful vasodilators known, and sensory nerves containing CGRP provide extensive innervation of blood vessels. 1, 2 Furthermore, CGRP and/or CGRP receptor expression are increased in several models of hypertension, including that induced by infusion of the vasoconstrictor peptide angiotensin II (Ang-II). [3] [4] [5] [6] Although pharmacological blockade of CGRP receptors does not influence mean arterial pressure (MAP) of normotensive subjects, receptor blockade increases the severity of hypertension in several experimental models. 6 -8 These findings suggest that endogenous CGRP operates through a negative-feedback mechanism to oppose the development of hypertension.
Although it is reasonable to attribute antihypertensive actions of CGRP to its vasodilator activity, other mechanisms may also be involved. CGRP and CGRP receptors are expressed in sensory nerves and brain regions that powerfully influence blood pressure via their effects on parasympathetic and sympathetic nerve activity. 2,9 -11 Previous studies examining autonomic responses to acute administration of CGRP have demonstrated variable responses that were dependent on site of injection and dose. [12] [13] [14] [15] [16] [17] The baroreceptor reflex is a major regulator of arterial blood pressure. 18 CGRP has been implicated in modulation of baroreflex sensitivity, but its role and importance remain unclear. 9, 16, 17 The baroreflex buffers fluctuations in blood pressure by evoking reflex changes in heart rate (HR) and vascular resistance. Therefore, high baroreflex sensitivity reduces blood pressure variability and increases HR variability. Decreases in baroreflex sensitivity and HR variability, as well as associated increases in blood pressure variability, increase cardiovascular risk. 19, 20 Thus, a favorable influence of CGRP on autonomic regulation may provide additional protection beyond its blood pressure-lowering effect in hypertension. Indeed, such a favorable action of CGRP is suggested by the finding that MAP, HR, and sympathetic tone are increased and cardiac parasympathetic tone is decreased in CGRP-deficient mice, 21, 22 although contradictory data have also been reported. 23 The discovery of the molecular components of the CGRP receptor complex has created new avenues for investigating the role of CGRP in blood pressure regulation. The CGRP receptor is a multimeric G protein-coupled receptor complex consisting of calcitonin-like receptor and receptor activitymodifying protein 1 (RAMP1). 24 RAMP1 is a single-pass transmembrane protein that is required for high-affinity binding of CGRP and trafficking of the receptor to the cell surface. 25 Studies from our laboratory (Z.Z., A.F.R.) have demonstrated that increasing expression of RAMP1 in trigeminal ganglia 26 and vascular smooth muscle 27, 28 enhances functional responses to CGRP, both in vitro and in vivo. Thus, RAMP1 is rate limiting for CGRP receptor-mediated signaling.
On the basis of these findings, we hypothesized that transgenic upregulation of RAMP1 will enhance the antihypertensive actions of endogenous CGRP in vivo. To test this hypothesis, we generated transgenic mice with ubiquitous expression of human RAMP1 (hRAMP1) in all tissues and compared cardiovascular and autonomic phenotypes in the hRAMP1 transgenic mice and littermate controls before and during chronic infusion of a pressor dose of Ang-II.
Methods

Animals
Experiments were performed on male mice at 10 to 20 weeks of age. The mice were maintained in a 12:12 hour light-dark cycle (6:00 AM to 6:00 PM), fed normal mouse chow, and had access to water ad libitum. All of the procedures were performed in accordance with American Physiological Society and institutional guidelines.
Transgenic mice with green fluorescent protein (GFP) flanked by loxP sites followed by the hRAMP1 cDNA have been described. 26 Hemizygous GFP-hRAMP1 mice (strain 28412/3) were crossed with mice expressing cre recombinase under the control of the ubiquitous adenovirus EIIa promoter (B6.FVB-Tg[EIIa-cre]C5379Lmgd/J, stock No. 003724, Jackson Laboratory) to produce double transgenic EIIa/hRAMP1 mice, referred to here as hRAMP1 mice. Polymerase chain reaction (PCR) genotyping, using primers detecting hRAMP1 (GenBank accession No. NC_000002), SV40 (GenBank accession No. NC001669), and cre, was performed as described. 26 PCR products with a predicted size of 371 bp for hRAMP1 and 400 bp for cre were analyzed by gel electrophoresis and confirmed by sequencing.
hRAMP1 expression was confirmed in multiple tissues by RT-PCR. Tissues were also analyzed by real-time quantitative PCR to determine the mRNA expression levels of both hRAMP1 and the endogenous mouse RAMP1 (mRAMP1) in hRAMP1 mice (nϭ3) and littermate controls (nϭ3). For a description of the methods used for detection and measurement of mRNA expression, please see the online Data Supplement at http://hyper.ahajournals.org.
Cardiovascular and Autonomic Assessment Before and During Ang-II Infusion
A radiotelemetry probe (Data Sciences International) was inserted into the thoracic aorta via the left common carotid artery in anesthetized mice for measurement of arterial blood pressure. 29 The implant surgical procedure and care of the mice are described in the online Data Supplement.
Mice were allowed to recover from the transmitter implantation for 5 days before baseline measurements were made. Thereafter, diurnal variations in blood pressure, HR, and locomotor activity were measured over a minimum of 24 hours at a sampling rate of 500 Hz for 10 seconds once every 5 minutes using the Dataquest ART Acquisition software (version Gold 4.0, Data Sciences International; nϭ7 for each group of mice). Blood pressure was continuously recorded at a higher sampling frequency (2000 Hz) for 1 hour, between 10:00 AM and 3:00 PM, to collect data for assessment of baroreflex sensitivity, blood pressure, and HR variability (nϭ7 for each group). This period of day, when mice are relatively inactive, was chosen to minimize the influences of physical activity and arousal. Pulse interval and HR were derived from the blood pressure waveform using the Data Sciences International software. Measurements of spontaneous locomotor activity were derived from the changes in transmitter signal strength associated with movement of the mouse.
After baseline measurements were obtained, mice were anesthetized, and an osmotic minipump (model 1002, ALZET) containing Ang-II was implanted subcutaneously. After recovery from surgery, 24-hour recordings of blood pressure, HR, and activity were made over the next 14 days (nϭ7 for each group). At the end of week 2, blood pressure was continuously recorded for 1 hour at 2000 Hz for assessment of baroreflex sensitivity and HR and blood pressure variability (nϭ5 for each group).
In additional groups of hRAMP1 (nϭ4) and control (nϭ3) mice, blood pressure responses to acute intravenous injection of the CGRP receptor antagonist CGRP (1 g/g), the Ang-II type 1 receptor (AT 1 R) antagonist losartan (10 g/g), and the ganglionic blocker chlorisondamine (12 g/g) were measured to estimate the contributions of endogenous CGRP, AT 1 R activation, and sympathetic nerve activity to the blood pressure level in Ang-II-infused mice. Drugs were injected via a chronically implanted jugular vein catheter, and blood pressure was measured by telemetry as described above. The methods are described in detail in the online Data Supplement. At the end of each experiment, mice were euthanized with pentobarbital (150 g/g, IP), and the radiotelemeters were removed, cleaned, and sterilized for future use.
Expression of AT 1 R, CGRP, and RAMP1 in Neuronal and Vascular Tissues
Prohypertensive and antihypertensive actions of Ang-II and CGRP, respectively, may involve changes in expression of AT 1 R, CGRP, and/or the CGRP receptor. To evaluate these possibilities, we measured AT 1 R, CGRP, and mRAMP1 expression by quantitative PCR in brain stem, dorsal root ganglia (DRG), aorta, and kidney of control and hRAMP1 mice with and without infusion of Ang-II. For a description of the procedures for removing tissues and performing quantitative PCR, please see text and Table S1 in the online Data Supplement.
Data Analysis
Diurnal variations in MAP, HR, and activity were calculated as the difference between average values measured over a 6-hour night period (6:00 PM to 12:00 AM) and average values measured over a 6-hour day period (8:00 AM to 2:00 PM). Baroreflex sensitivity for control of HR was calculated from spontaneous fluctuations in systolic arterial blood pressure and HR when the mice were active using the sequence technique. 30 Sequences of Ն4 consecutive blood pressure pulses where the systolic arterial pressure and pulse interval are positively correlated (r 2 Ͼ0.85) were detected using a customized software (HemoLab, version 2.3). Baroreflex sensitivity was calculated as the average slope of the systolic pressure-pulse interval relationships (change in milliseconds per change in millimeter of mercury).
Blood pressure and HR variability were calculated from beat-tobeat measurements of systolic arterial pressure and pulse interval recorded for 3 minutes when the mice were inactive using Hemolab and Batch Processor (version 0.5) software. The SD of pulse interval measurements provided a general measure of HR variability. The root mean square of successive differences in pulse intervals provided a measure of rapid, parasympathetic-mediated modulation of HR. 31 The SD of systolic arterial pressure measurements provided a measure of blood pressure variability.
The results are expressed as meanϮSEM. Significant differences were defined at PϽ0.05. An unpaired t test was used to compare between 2 groups. Either repeated-measures ANOVA with least significant difference post hoc test or paired t test was used to determine effects of Ang-II, CGRP , losartan, and chlorisondamine. ANOVA (2-factor) was used to determine effects of genotype and Ang-II on gene expression (StatView, SAS Institute).
Results hRAMP1 Transgenic Mice
The GFP-hRAMP1 mice were crossed with mice expressing cre recombinase under control of the EIIa promoter, which is active early in development and in all tissues 32 ( Figure 1A ). The resultant double-transgenic hRAMP1 mice expressed the hRAMP1 gene in all of the tissues ( Figure 1B ). As expected, there was loss of GFP fluorescence in the hRAMP1 mice. In some tissues, such as the heart, there was still patchy fluorescence ( Figure 1A ), which is in agreement with reported mosaic expression of the EIIa-cre transgene. 32 The levels of hRAMP1 and endogenous mRAMP1 gene expression in the hRAMP1 mice were determined by quantitative PCR using hRAMP1-and mRAMP1-specific primers. 26 The combined total of hRAMP1 and mRAMP1 RNA in different tissues of the hRAMP1 mice ranged from 5-to 15-fold greater than the endogenous mRAMP1 RNA level in tissues of control littermates ( Figure 1C ).
Cardiovascular/Autonomic Phenotypes Under Basal Conditions
Under basal conditions, MAP and locomotor activity (24-hour average) did not differ in control and hRAMP1 mice, whereas mean HR was significantly lower in hRAMP1 mice (573Ϯ14 versus 615Ϯ12 bpm in control mice; Figure 2A ). Furthermore, the diurnal night-day differences in MAP, HR, and locomotor activity were similar in control and hRAMP1 mice ( Figure 2B ).
GFP-hRAMP1
EIIa/hRAMP1 were detected from all tissues from both genotypes. hRAMP1 RNA was not detected from the double-transgenic mice when amplified in the absence of reverse transcriptase or when water was substituted for cDNA (data not shown). C, Quantitative PCR measurement of RAMP1 levels in EIIa/hRAMP1 mice (hR) and control littermates (C). The levels of hRAMP1 (h), mRAMP1 (m), and ␤-actin were determined by real-time PCR. The copies of RAMP1 RNAs were calculated from standard curves and normalized to 50 000 copies of ␤-actin mRNA (left). Right, Fold increase of total RAMP1 level in EIIa/hRAMP1 mice relative to control mice is indicated. Data are the mean from 3 mice in each group, with the SE from 3 independent experiments.
We also measured short-term blood pressure and HR variability and calculated spontaneous baroreflex sensitivity. Although MAP did not differ in the 2 groups of mice, systolic blood pressure variability (SD) was markedly reduced in hRAMP1 mice ( Figure 2C ). Conversely, overall HR variability (SD of pulse intervals) and rapid beat-to-beat variability attributed to parasympathetic modulation 31 were increased significantly in hRAMP1 mice ( Figure 2D ). Baroreflex sensitivity was markedly increased in hRAMP1 mice ( Figure 2E ). Increased baroreflex sensitivity was evident when blood pressure was increasing (up sequences) and when it was decreasing (down sequences), and the number of baroreflex sequences per 1000 heartbeats did not differ in control versus hRAMP1 mice (Table  S2 , please see the online Data Supplement).
Ang-II Hypertension and Autonomic Dysregulation Are Abrogated in hRAMP1 Mice
In control mice, Ang-II increased MAP progressively over time with the rise in pressure reaching significance on days 3 through 14 ( Figure 3A) . Infusion of the same dose of Ang-II in hRAMP1 mice did not increase MAP significantly until the 13th day of infusion, and the severity of hypertension was modest ( Figure 3A) . Mean HR and locomotor activity were not affected by Ang-II infusion ( Figure 3A) . Although Ang-II did not affect diurnal variations in MAP or locomotor activity in either group of mice, it essentially abolished diurnal variations in HR in control mice ( Figure 3B ). The lack of diurnal HR changes during Ang-II infusion was the result of a lower HR at night (Table S3) . Ang-II did not significantly reduce diurnal variations in HR in hRAMP1 mice ( Figure 3B and Table S3 ).
Ang-II infusion increased blood pressure variability, decreased HR variability, and decreased baroreflex sensitivity in control mice (Figure 4) . The Ang-II-induced increase in blood pressure variability was abolished, whereas the decrease in HR variability was reversed to an increase in hRAMP1 mice ( Figure 4) . The Ang-II-induced decrease in baroreflex sensitivity was evident for both up and down sequences (Table S2) and was less severe in hRAMP1 mice (Ϫ32Ϯ6%) than in control mice (Ϫ53Ϯ4%; PϽ0.05; Figure 4 ).
Mechanisms Influencing Blood Pressure Level During Ang-II Infusion
Previous studies have demonstrated that pharmacological blockade of CGRP receptors increases MAP in several models of hypertension while having little or no effect on MAP in normotensive animals. 6 -8 To estimate the contribution of endogenous CGRP to MAP in Ang-II-infused mice, we measured the blood pressure response to intravenous injection of the CGRP receptor antagonist CGRP . CGRP increased MAP in control mice (PϽ0.05), and this effect was enhanced significantly in hRAMP1 mice ( Figure  5 ). Thus, endogenous CGRP protects against Ang-II hypertension, and the protection is potentiated by upregulation of the CGRP receptor subunit RAMP1.
The AT 1 R blocker losartan caused small but significant decreases in MAP in both control and hRAMP1 mice infused with Ang-II that did not differ in magnitude between the groups ( Figure 5 ). In contrast, injection of the ganglionic blocker chlorisondamine markedly decreased MAP in both groups of mice with the magnitude of the decrease in pressure being significantly greater in control mice ( Figure 5 ). These results suggest that reduced sympathetic-mediated vasoconstriction may contribute to the lower MAP in hRAMP1 mice versus control mice. 
Expression of AT 1 R, CGRP, and RAMP1 in Control and hRAMP1 Mice
Ang-II infusion increased AT 1 R expression (Ϸ20 fold) and CGRP expression (Ϸ2 fold) in the brain stem of control mice (Table; PϽ0.05) but did not affect expression of these genes in the aorta, DRG, or kidney (Table) . In contrast, in hRAMP1 mice, Ang-II failed to increase brain stem AT 1 R expression and increased brain stem CGRP expression to higher levels (Table) . Ang-II infusion increased mRAMP1 expression in the brain stem of both control and hRAMP1 mice but decreased mRAMP1 expression in the aorta and DRG (Table) . Furthermore, mRAMP1 expression was upregulated in the brain stem of the transgenic hRAMP1 mice (1.5-to 2.0-fold), both at baseline and during Ang-II infusion (Table) . CGRP and AT 1 R expressions were increased by Ϸ2 fold in DRG of hRAMP1 mice (PϽ0.05; Table) .
Discussion
We have created a mouse model that exhibits ubiquitous transgenic expression of hRAMP1 with increased RAMP1 levels in all tissues examined. We provide here the first full report of the phenotype of these mice. Under baseline conditions, the hRAMP1 mice are normotensive. The normal MAP is accompanied by striking, favorable changes in . Transgenic hRAMP1 expression abrogates deleterious effects of Ang-II on autonomic regulation. The Ang-II-induced increase in blood pressure (BP) variability was abolished, the decrease in HR variability was reversed to increased variability, and the decrease in baroreflex sensitivity was less pronounced in hRAMP1 mice vs control mice. Measurements were obtained at baseline (BL) and after 2 weeks of Ang-II infusion in control (nϭ5) and hRAMP1 (nϭ5) mice. A, Systolic BP variability (SD). B, HR variability (pulse interval SD, PI-SD). C, HR variability reflecting parasympathetic modulation (root mean square of successive differences in pulse interval; RMSSD 
Cardiovascular/Autonomic Phenotypes in hRAMP1 Mice Under Basal Conditions
The normal MAP observed in the hRAMP1 mice under basal conditions is consistent with the failure of peripheral administration of CGRP receptor antagonists to increase MAP in normotensive animals in previous studies. 6 -8 However, we did observe improved autonomic regulation in the hRAMP1 mice under basal conditions. This suggests that hRAMP1 levels are important for normal cardiovascular regulation. This conclusion is in agreement with results from CGRP 21, 22 and RAMP1 33 knockout mice that are hypertensive, although this was not seen in one CGRP Ϫ/Ϫ line. 23 Our findings particularly complement the results of Oh-hashi et al, 21 who demonstrated increased sympathetic tone and decreased parasympathetic tone in hypertensive ␣-CGRP Ϫ/Ϫ mice. The failure of peripherally administered CGRP receptor antagonists to increase MAP in healthy animals may reflect poor penetrance of the antagonist into the central nervous system. CGRP and its receptor are expressed in central nervous system sites involved in autonomic regulation, including the nucleus tractus solitarius, hypothalamus, dorsal motor nucleus of the vagus, nucleus ambiguus, and amygdala. 2, 10, 11 CGRP is also expressed in carotid sinus nerves, 9 suggesting its presence in baroreceptor afferents.
In previous studies, CGRP microinjected into central nervous system sites has usually resulted in increases in sympathetic activity, HR, and MAP, [12] [13] [14] although opposite responses were sometimes observed depending on dose and site of injection. 15, 17 CGRP has been reported to either enhance or inhibit baroreflex sensitivity through undefined central mechanisms. 16, 17 Thus, our finding of high baroreflex sensitivity and HR variability and low blood pressure variability in hRAMP1 mice under basal conditions could not have been easily predicted from the previous acute studies. More research is needed to define the mechanisms of the enhanced autonomic regulation in hRAMP1 mice.
RAMP1 in Hypertension
The results of the present study are consistent with the established role of endogenous CGRP to oppose the development of most types of hypertension. 4 -8 We chose the Ang-II infusion model of hypertension because the model is well characterized in a variety of species, including mice, 6,34 -37 and Ang-II is established as an important cause of hypertension in humans. 38 Although direct Ang-II-induced vasoconstriction may cause the initial rise in MAP, increases in central sympathetic drive and blunting of baroreflexmediated decreases in sympathetic activity and HR play predominant roles when Ang-II is infused chronically over several days to weeks. [35] [36] [37] Although the mechanism of the antihypertensive effect of RAMP1 is not yet fully understood, our results, along with the established strong neurogenic contribution to Ang-II hypertension, suggest that high baroreflex sensitivity and suppression of central sympathetic drive are involved. The AT 1 R blocker losartan caused small decreases in MAP in control and hRAMP1 mice infused with Ang-II ( Figure 5B ), whereas the ganglionic blocker chlorisondamine caused large decreases in MAP that were significantly attenuated in the hRAMP1 mice ( Figure 5C ). These results are consistent with high sympathetic vasomotor tone contributing to hypertension in the Ang-II-infused control mice and reduced sympathetic tone contributing to the lower MAP in hRAMP1 mice. The meager depressor response to losartan in both groups of in control and hRAMP1 mice. The greater increase in blood pressure in hRAMP1 mice suggests that enhanced responsiveness to endogenous CGRP contributes to the lower MAP in these mice. B, Shown are the decreases in MAP that occurred in response to the AT 1 R blocker losartan. The small and similar response in control and hRAMP1 mice suggests that differences in AT 1 R signaling do not explain the differences in MAP between the groups. C, Shown are the decreases in MAP in response to the ganglionic blocker chlorisondamine. The attenuation of the depressor response in hRAMP1 mice suggests that reduced sympathetic tone contributes to the lower MAP in these mice. MAP measured during Ang-II infusion before injection of CGRP , losartan, and chlorisondamine was significantly lower in hRAMP1 mice (126Ϯ1 mm Hg) compared with control mice (147Ϯ3 mm Hg; PϽ0.05). Number of mice per group: control, nϭ3; hRAMP1, nϭ4. *Data show significant change in MAP after injection of CGRP , losartan, or chlorisondamine, PϽ0.05. †Data show significant difference in the magnitude of response to drug in hRAMP1 vs control mice, PϽ0.05. mice may reflect desensitization of vascular AT 1 R during the sustained 1-to 2-week infusion of Ang-II and/or limited penetrance of acutely administered (intravenous) losartan into the brain. A progressive decrease in the magnitude of the acute depressor response to AT 1 R blockade and enhancement of the depressor response to ganglionic blockade during sustained Ang-II-induced hypertension have been shown previously in rats, 35 suggesting the predominant contribution of central AT 1 R to the hypertensive effect of Ang-II.
Our gene expression data support the functional results. Ang-II infusion increased AT 1 R mRNA expression selectively in the brain stem of control mice, an effect that was abrogated in hRAMP1 mice (Table) . Increased AT 1 R expression in the brain stem has been associated with increased sympathetic nerve activity in heart failure. 39 Peripheral AT 1 R expression in the aorta, kidney, and DRG was similar in control and hRAMP1 mice, suggesting that the lower MAP in hRAMP1 mice was not caused by downregulation of peripheral AT 1 R.
Ang-II also increased mRAMP1 expression selectively in the brain stem, and both mRAMP1 and CGRP expressions in the brain stem were significantly elevated in Ang-II-infused hRAMP1 mice versus control mice (Table) . hRAMP1 expression in the brain stem of the transgenic mice was confirmed (see Figure 1B) . We speculate that reduced expression of AT 1 R and increased expression of RAMP1 and CGRP in the brain stem may have contributed to the higher baroreflex sensitivity, lower sympathetic tone, and attenuation of hypertension in Ang-II-infused hRAMP1 mice. We also observed that CGRP expression was increased in DRG of hRAMP1 mice (Table) . CGRP-positive sensory neurons in DRG provide widespread innervation of blood vessels and are a major source of circulating CGRP. 1,2 Thus, CGRP-induced vasodilation may contribute to the lower MAP in hRAMP1 mice. Future studies will be required to further define the central and peripheral mechanisms by which upregulation of RAMP1 enhances autonomic regulation and reduces blood pressure. It will also be important to determine whether the changes in AT 1 R, CGRP, and RAMP1 mRNA expression shown here translate to changes in protein expression.
Although we have focused on the CGRP receptor, it is possible that interactions between RAMP1 with other G protein-coupled receptors 40 may contribute to the autonomic and cardiovascular phenotypes in hRAMP1 mice. RAMP1 interacts with the calcitonin receptor to generate an amylin receptor that can also bind CGRP. 41 RAMP1/calcitonin-like receptors are also activated by intermedin, the newest member of the calcitonin/CGRP peptide family. 42 Furthermore, it is possible that RAMP1 overexpression may modulate the interactions of calcitonin-like receptor with RAMP2 or RAMP3, which generate adrenomedullin receptors. 25, 43 Although functional responses to upregulation of RAMP1 may involve other agonists in addition to CGRP, our finding that the pressor response to the CGRP receptor antagonist CGRP was enhanced in hRAMP1 mice suggests that CGRP contributes to the lower MAP in these mice ( Figure 5A ).
It is important to note that the clinical benefits of upregulating RAMP1 expression in hypertension are likely to extend beyond its blood pressure-lowering effect. Increased blood pressure variability and low values of baroreflex sensitivity, HR variability, and diurnal HR fluctuations increase the risk of cardiovascular events and death in patients with hypertension and myocardial infarction. 19, 20, 44 The deleterious effects of Ang-II infusion on each of these risk factors in control mice were abrogated or reversed in hRAMP1 mice.
Perspectives
We have investigated whether upregulation of a regulatory subunit of the CGRP receptor, RAMP1, may enhance the protective actions of CGRP or related peptides in the cardiovascular system. Indeed, changes in RAMP1 levels under various conditions have been reported, including hypertension, 4, 6 heart failure, 45 pregnancy, 46 and ureteral obstruction. 47 The magnitude of increase in RAMP1 mRNA expression in the failing heart (Ϸ3-fold) and the obstructed kidney (Ϸ13-fold) 45, 47 approach the levels that we observed in the hRAMP1 mice (Ϸ5-to 15-fold; Figure 1 ). On the basis of these reports and our results obtained from the genetically engineered hRAMP1 mice, it seems likely that dynamic changes in RAMP1 expression will have functional implications in cardiovascular pathologies and identify RAMP1 as a therapeutic target in hypertension. The feasibility of modulating RAMP1 for therapeutic benefit has been established by the efficacy of RAMP1 antagonists for treating migraines. 48, 49 Analysis of the benefits and possible adverse effects of antagonizing and enhancing CGRP-RAMP1 signaling and development of methods to target therapies in a tissuespecific manner will be needed to optimize the therapeutic potential.
Ang-II infusion. The catheter was exteriorized at the back of the neck, the incision site was closed with suture (coated Vicryl 6-0), and the mouse was allowed to recover for a minimum of one day before measuring blood pressure and heart rate responses to IV injections of the antagonists in the conscious state. CGRP , losartan, and chlorisondamine were administered on days 9, 10 and 11 of Ang-II infusion, respectively, and only one drug was administered on a given day. Peak blood pressure responses to the three drugs were measured within 2.5, 8 and 11 minutes after injection, respectively. Mean arterial pressure (MAP) was averaged over 10s, 30s and 30s during the peak response for CGRP , losartan, and chlorisondamine, respectively; and the values were subtracted from baseline measurements recorded before injection (averaged over 30s).
Measurement of AT 1 R, CGRP and RAMP1 expression by qPCR
Mice were deeply anesthetized with sodium pentobarbital (~100 µg/g, IP) and placed in the supine position. The thoracic and abdominal aorta, both kidneys, and cervical and upper thoracic DRG were exposed by a midline sternotomy and abdominal incision, and sequentially removed in that order using a scalpel. The DRGs were pooled as were the two kidneys. The brainstem was approached via a dorsal midline craniotomy, identified by standard landmarks, and removed using a scalpel. Upon removal, the tissues were rapidly put into screw-top tubes that were immediately placed into liquid nitrogen, and stored at -80 o C. The tissues were thawed on ice and mechanically homogenized in preparation for qPCR analysis. Total RNA was extracted using Trizol regent (Invitrogen) according to the manufacturer's recommendations, and reverse transcribed into cDNA by using AffinityScript™ QPCR cDNA Synthesis Kit (Stratagene) according to the manufacturer's protocol. The quantitative analysis of the mRNA expression was carried out by using Model 7000 real-time PCR system (ABI). Brilliant SYBR Green QPCR Master Mix (Stratagene) and primers were used according to the protocol provided by the manufacturer. Gene-specific primers for real time qPCR were designed using Primer Designer 4.20 software (Scientific Educational Software, Cary, NC), and the oligomers were purchased from Integrated DNA Technologies (IDT, Coralville, IA). The sequences of the primers are shown in Table S1 .
The cycle protocol included: 95°C for 10 min, followed by 40 cycles of 95°C for 30 s and annealing/extension at 56°C for 1 min and 72°C for 30 s. A dissociation step (generating a thermal melt curve) was added to check the primer specification. Measurements were excluded if the melt curve was not homogenous. AT 1 R, CGRP, mRAMP1, and hRAMP1 expression measurements were normalized to expression of 18S ribosomal RNA. Relative gene expression levels were calculated using the ∆∆C T method which enables quantitation of target sequences relative to a reference control (3). As our reference control, we used the mRNA levels in DRGs from one of the hRAMP1 mice not subjected to Ang-II infusion. As expected, hRAMP1 was expressed at high levels in all tissues of transgenic mice and was essentially undetectable in tissues from control mice with the exception of one of the Ang-II infused control mice. Therefore, data from that mouse was excluded from all analyses. 
